Last reviewed · How we verify
Auto-CD34+ cells
Auto-CD34+ cells are autologous CD34+ hematopoietic stem cells mobilized and collected from a patient's own bone marrow or peripheral blood, then reinfused to promote tissue regeneration and repair.
Auto-CD34+ cells are autologous CD34+ hematopoietic stem cells mobilized and collected from a patient's own bone marrow or peripheral blood, then reinfused to promote tissue regeneration and repair. Used for Critical limb ischemia, Severe peripheral artery disease.
At a glance
| Generic name | Auto-CD34+ cells |
|---|---|
| Sponsor | Lisata Therapeutics, Inc. |
| Drug class | Cell therapy |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine / Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
CD34+ cells are hematopoietic stem and progenitor cells that can differentiate into various cell types and secrete paracrine factors that promote angiogenesis, reduce inflammation, and support tissue healing. In Lisata's approach, these autologous cells are mobilized using a proprietary mobilization regimen, collected via apheresis, and reinfused into patients to enhance regenerative capacity in damaged or ischemic tissues. The mechanism leverages the cells' inherent ability to home to injury sites and promote vascular and tissue recovery.
Approved indications
- Critical limb ischemia
- Severe peripheral artery disease
Common side effects
- Injection site reactions
- Mobilization-related adverse events
- Transient fever or flu-like symptoms
Key clinical trials
- Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A (PHASE1)
- Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A (PHASE1)
- Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation (PHASE4)
- Auto Transplant for High Risk or Relapsed Solid or CNS Tumors (NA)
- Scleroderma: Cyclophosphamide or Transplantation (PHASE2, PHASE3)
- CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma (PHASE2)
- Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) (PHASE3)
- ACT34-CMI -- Adult Autologous CD34+ Cells (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Auto-CD34+ cells CI brief — competitive landscape report
- Auto-CD34+ cells updates RSS · CI watch RSS
- Lisata Therapeutics, Inc. portfolio CI